17th ISNI Annual Conference

A fresh look at Neuroinflammation

Rabin Center, Tel Aviv • 8-9.6.2017

Scientific Program
## THURSDAY 8.6.2017
### GENERAL AND EXPERIMENTAL NEUROIMMUNOLOGY

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chairpersons</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:20</td>
<td>Gathering and Registration</td>
<td></td>
</tr>
<tr>
<td>09:20-09:30</td>
<td>Greetings &amp; Opening Remarks</td>
<td>Dimitrios Karussis, President of the Israeli Neuroimmunological Society</td>
</tr>
<tr>
<td>09:30-11:15</td>
<td>FIRST SESSION: GENERAL NEUROIMMUNOLOGY</td>
<td>Arnon Karni, Rolls Asya</td>
</tr>
<tr>
<td>09:30-09:45</td>
<td>High-dimensional Mass Cytometry Characterization of the Brain’s Immune Compartment</td>
<td>Ben Korin, Tamar Ben-Shaanan, Maya Schiller, Tania Dubovik, Hilla Azulay-Debby, Nadia Bushnak, Tamar Koren, Asya Rolls Technion, Haifa</td>
</tr>
<tr>
<td>09:45-10:00</td>
<td>Dysfunctional brain stem cells in Alzheimer’s disease mice</td>
<td>Tamir Ben-Hur, Nina Fainstein Hebrew University, Jerusalem</td>
</tr>
<tr>
<td>10:00-10:15</td>
<td>Regulatory role of cytosolic Phospholipase A2 Alpha in induction of CD40 in Microglia</td>
<td>Yafa Fetfet Malada-Edelstein, Nurit Hadad, Rachel Levy Ben Gurion University, Be’er -Sheva</td>
</tr>
<tr>
<td>10:15-10:30</td>
<td>Expression of mutated PS1 in microglia increase microglia pro-inflammatory profile</td>
<td>Alon Rabinovich, Dorit Farfara, Dan Frenkel Tel Aviv University</td>
</tr>
<tr>
<td>10:30-10:45</td>
<td>Deficiency in Parkinson’s related gene DJ-1 impairs microglia degradation and phagocytosis of alpha-synuclein</td>
<td>Yuval Nash, Eran Schmukler, Dorit Trudler, Ronit Pinkas-Kramarski, Dan Frenkel Tel Aviv University</td>
</tr>
<tr>
<td>10:45-11:00</td>
<td>Prothrombotic Mechanisms in Patients with Congenital p.Cys89Tyr Mutation in CD59</td>
<td>Dror Mevorach, Hebrew University, Jerusalem</td>
</tr>
</tbody>
</table>
11:00-11:15  A comprehensive evaluation of serum microRNAs as potential biomarkers in multiple sclerosis
Keren Regev, Brian Healy, Anu Paul, Maria Mazzola, Rohit Bakshi, Roopali Gandhi, Howard Weiner
Harvard University, Boston MA

11:15-11:45  Coffee break, Exhibition & Poster viewing

11:45-13:00  SECOND SESSION: INVITED LECTURES
Chairpersons: Joab Chapman, Oded Abramsky

11:45-12:25  The role of neuro-inflammation in neurodegeneration and regeneration
Michal Schwartz, Weizmann Institute, Rehovot

12:25-13:00  Autoimmunity of the Autonomic system
Vanda Lennon, Mayo Clinic, Rochester, USA

13:00-14:00  Lunch break and poster viewing

14:00-15:30  THIRD SESSION: THEMED LECTURES
Chairpersons: Talma Brenner, Alon Monsonego

14:00-14:30  Pediatric Neuroimmunology
Yael Hacohen, UCL University, UK

14:30-14:50  Inflammatory aspects of stroke
Ronen Leker, Hebrew University, Jerusalem

14:50-15:10  Inflammatory aspects of epilepsy
Dana Eckstein, Hebrew University, Jerusalem

15:10-15:30  Inflammatory aspects of dementia
Alon Monsonego, Ben Gurion University Be’er - Sheva
Amos Korczyn, Tel Aviv University

15:30-15:45  Coffee break, Exhibition & Poster viewing
15:45-16:00 Blockage of BMP-2 Signaling, either by Neutralizing Ab, or by Small Molecules, Ameliorates Relapsing-Experimental Autoimmune Encephalomyelitis by Induction of Neurogenesis and Oligodendrogenesis
Karin Fainberg, Maya Golan, Arnon Karni, Tel Aviv University

16:00-16:15 The mechanism of action of laquinimod: Modulation of CNS inflammation via activation of the aryl hydrocarbon receptor
Joel Kaye, Francisco J. Quintana, Neta Zach, Ralph Laufer
Tel Aviv University

16:15-16:30 Gene expression profile characterizing the effect of laquinimod in peripheral blood cells from primary progressive multiple sclerosis patients
Rina Zilkha-Falb, Michael Gurevich, Anat Achiron
Sheba Medical Center

16:30-16:45 Evaluation of the predictive value of three serum and CSF Biomarkers for the development of CDMS following a CIS
Nour Eddine Yaghmour, Panayiota Petrou, Ibrahim Kassis, Michel Halimi, Dimitrios Karussis
Hebrew University, Jerusalem

16:45-17:00 Dimethyl Fumarate therapy modulates B cells phenotype and functional markers, increasing IL10+ B regulatory cell subsets in patients with Multiple Sclerosis
Elsebeth Staun-Ram, Eiman Najjar, Ariel Miller, Technion, Haifa

17:00-17:15 “Neuralized” Mesenchymal Stem Cells: Novel Therapy Paradigm for the treatment of Multiple Sclerosis
Ibrahim Kassis, Moriel Ben-Zwi, Panayiota Petrou, Dimitrios Karussis
Hebrew University, Jerusalem

17:15-17:30 Human embryonic stem cell-derived oligodendrocyte progenitor cells provide long-term immune-regulation and protection in a chronic-relapsing model of multiple sclerosis
Yossi Nishri, David Hampton, Etti Ben Shushan, Nina Fainstein, Michal Aharonowiz, Dario Magnani, Benjamin E Reubinoff, Siddharthan Chandran, Tamir Ben-Hur
Hebrew University, Jerusalem
17:30-17:45 Color vision impairment following optic neuritis and its association with retinal atrophy
Netta Levin, Michael Devereux, Atira Bick, Nick Baker, Ari Green
UCSF, San Francisco CA

17:45-18:45 Business meeting and elections of the Israeli Neuroimmunological society (members only)

17:45-18:45 Tour of the Rabin Center

19:30-23:00 Social evening (organized by the Neuroimmunological Society):
Andromeda restaurant
(Lecture: The efforts of science, religion and philosophy to answer the “big questions”; Contradictory approaches or harmonic co-existence?)
FRIDAY 9.6.2017

CLINICAL NEUROIMMUNOLOGY AND MULTIPLE SCLEROSIS

08:00-10:00  FIFTH SESSION: TEACHING COURSE
Chairpersons: Nathan Karin, Adi Vaknin-Dembinsky

08:00-10:00  Introductory course in basic principles of clinical and experimental Neuroimmunology
Olaf Stuve, Southwestern University Dallas, TX
Sponsored by: Merck

10:00-10:30  Coffee Break & Exhibition

10:30-13:30  SIXTH SESSION: MULTIPLE SCLEROSIS
Chairpersons: Dimitrios Karussis, Ariel Miller

10:30-11:15  MRI as the optimal biomarker in MS
Maria-Pia Sormani, University of Genoa, Italy

11:15-11:45  Rescue immunotherapy in MS
Olaf Stuve, Southwestern University, Dallas, TX
Sponsored by: Merck

11:45-12:15  Targeting innate immune system in MS
Dimitrios Karussis, Hebrew University, Jerusalem
Sponsored by: Medison

12:15-13:15  The limitations of current immunomodulating treatments for MS and the new therapeutic targets for the disease
Mark Freedman, Ottawa University Ottawa, Canada
Sponsored by: Roche

13:15  Questions and Roundtable discussion

Sponsored by:
Platinum
Merck, Medison, Roche

Gold
Teva, Sanofi, Genzyme

Silver
Novartis Pharmaceuticals

Bronze
Peprotech